Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C

BACKGROUND: Patients with substance use disorders (SUD) and chronic hepatitis C virus infection (HCV) have limited access to direct-acting antivirals (DAAs) due to multilevel issues related to providers (eg, concern about reinfection); patients (eg, refusal); payers (eg, prior authorization); and health system structure, although clinical guidelines recommend timely DAA treatment for patients with SUD and HCV. Effects of DAAs on real-world health care utilization and costs among these patients is unknown. OBJECTIVE: To compare changes in medical service utilization and costs related to liver, SUD, and all-cause morbidity in patients with SUD and HCV treated with DAAs (DAA group) vs not treated with DAAs (non-DAA group). METHODS: We conducted a retrospective cohort study using MarketScan Commercial and Medicare Supplemental Claims databases (2012-2018) for newly diagnosed HCV treatment-naive adults with SUD. We used difference-in-differences analyses, stratified by cirrhosis status, to determine the adjusted ratio of rate ratio (RoRR) to assess the difference in the relative changes from the pre- to posttreatment periods between the 2 groups. RESULTS: 6,266 patients with SUD and HCV were identified. Of these patients who also had cirrhosis (n = 607), 49% (n = 298) initiated DAA therapy for HCV, whereas of those without cirrhosis (n = 5,659), 22% (n = 1,219) initiated DAAs. For patients with cirrhosis (n = 607), the liver-related costs decreased by $6,213 (95% CI = −$8,571, −$3,856) for the DAA group and $1,585 (95% CI = −$4,659, $1,490) for the non-DAA group. The relative decreases in the rate of liver-related costs were larger for the DAA group than for the non-DAA group, and the relative changes between groups were significantly different (RoRR = 0.37, 95% CI = 0.19-0.73). There was no difference in the relative changes after DAAs in the rate of SUD-related visits/costs or all-cause costs between the 2 groups. For patients without cirrhosis (n = 5,659), a similar association was observed. Besides, the relative decreases in the rate of SUD-related emergency department (ED) visits (RoRR = 0.54, 95% CI = 0.38-0.77); SUD-related long-term care visits (RoRR = 0.30, 95% CI = 0.13-0.73); all-cause ED visits (RoRR = 0.75, 95% CI = 0.64-0.88); and all-cause long term-care visits (RoRR = 0.36, 95% CI = 0.18-0.72) were larger in the DAA group than in the non-DAA group. CONCLUSIONS: DAAs are associated with a significant decrease in the rate of SUD-related ED visits and liver-related costs without increasing the rate of all-cause costs among patients with SUD and HCV, suggesting that the benefits of DAAs extended beyond liver-related outcomes, especially in this disadvantaged population.

[1]  Haesuk Park,et al.  The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders , 2021, Journal of managed care & specialty pharmacy.

[2]  R. Cook,et al.  The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders , 2021, Hepatology.

[3]  Joshua D. Brown,et al.  Impact of hepatitis C virus treatment on the risk of non‐hepatic cancers among hepatitis C virus‐infected patients in the US , 2020, Alimentary pharmacology & therapeutics.

[4]  T. Mattingly,et al.  Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review , 2020, PharmacoEconomics.

[5]  R. Feldman,et al.  Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries , 2020, JAMA network open.

[6]  C. Stedman,et al.  Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Christine Y. Lu,et al.  Cost burden of hepatitis C virus treatment in commercially insured patients. , 2019, The American journal of managed care.

[8]  J. Dillon,et al.  Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. , 2019, The International journal on drug policy.

[9]  J. Lazarus,et al.  Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. , 2019, The International journal on drug policy.

[10]  E. Wood,et al.  Disparities in uptake of direct‐acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[11]  S. Patel,et al.  Behavioral Health Integration With Primary Care: Implementation Experience and Impacts From the State Innovation Model Round 1 States. , 2019, The Milbank quarterly.

[12]  C. Latkin,et al.  Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. , 2019, Journal of substance abuse treatment.

[13]  Haesuk Park,et al.  Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States , 2019, Hepatology.

[14]  Andreina A Ottman,et al.  Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals , 2019, The Annals of pharmacotherapy.

[15]  Jonathan Mermin,et al.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016 , 2018, Hepatology.

[16]  T. Rhodes,et al.  Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. , 2018, The International journal on drug policy.

[17]  Alex H. S. Harris,et al.  Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data , 2018, Journal of addiction medicine.

[18]  B. Linas,et al.  A Guide to the Economics of Hepatitis C Virus Cure in 2017. , 2018, Infectious disease clinics of North America.

[19]  Z. Butt,et al.  Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. , 2018, The International journal on drug policy.

[20]  M. Socías,et al.  Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review , 2018, JMIR research protocols.

[21]  P. Deb,et al.  Modeling Health Care Expenditures and Use. , 2018, Annual review of public health.

[22]  H. Masur,et al.  Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study , 2018 .

[23]  P. Read,et al.  Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.

[24]  W. Schaffner,et al.  Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population , 2018, Epidemiology and Infection.

[25]  G. Dore,et al.  Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies , 2018, Open forum infectious diseases.

[26]  Benjamin P Linas,et al.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.

[27]  Dongmu Zhang,et al.  Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Yager,et al.  The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. , 2018, The American journal of psychiatry.

[29]  Rahi Abouk,et al.  Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths , 2017, JAMA.

[30]  Likang Xu,et al.  Annual surveillance report of drug-related risks and outcomes -- United States, 2017 , 2017 .

[31]  S. Trudeau,et al.  Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records , 2017, Clinical epidemiology.

[32]  D. Fierer,et al.  Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection , 2017, Addictive disorders & their treatment.

[33]  Minjun Chen,et al.  Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury? , 2017, Gastroenterology.

[34]  N. Gupta,et al.  Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. , 2017, Journal of substance abuse treatment.

[35]  P. Gustafson,et al.  Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. , 2017, The lancet. Gastroenterology & hepatology.

[36]  J. Tor,et al.  Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections , 2016, World journal of hepatology.

[37]  T. Ayer,et al.  Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals , 2016, Hepatology.

[38]  D. Nickle,et al.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.

[39]  Christopher R. Taber,et al.  Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups , 2016, Applied Health Economics and Health Policy.

[40]  D. Vlahov,et al.  Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs , 2016, Substance use & misuse.

[41]  Walid F. Gellad,et al.  Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. , 2016, Addiction.

[42]  T. Rhodes,et al.  Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. , 2015, The International journal on drug policy.

[43]  M. Ciarleglio,et al.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade , 2015, PloS one.

[44]  S. Holmberg,et al.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs , 2015, Annals of Internal Medicine.

[45]  G. Dore,et al.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.

[46]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[47]  M. King,et al.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. , 2015, Journal of hepatology.

[48]  Patrick B Ryan,et al.  The impact of standardizing the definition of visits on the consistency of multi-database observational health research , 2015, BMC Medical Research Methodology.

[49]  David S Goldberg,et al.  Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data , 2015, Pharmacoepidemiology and drug safety.

[50]  A. Ryan,et al.  Methods for evaluating changes in health care policy: the difference-in-differences approach. , 2014, JAMA.

[51]  Elizabeth A. Stuart,et al.  Using propensity scores in difference-in-differences models to estimate the effects of a policy change , 2014, Health Services and Outcomes Research Methodology.

[52]  R J Glynn,et al.  Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs , 2014, Journal of internal medicine.

[53]  William H Crown,et al.  Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods , 2014, Applied Health Economics and Health Policy.

[54]  J. B. Layton,et al.  Propensity Score Methods for Confounding Control in Nonexperimental Research , 2013, Circulation. Cardiovascular quality and outcomes.

[55]  Bryan Dowd,et al.  Interaction Terms in Nonlinear Models , 2002 .

[56]  H. El‐Serag,et al.  Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States , 2011, Hepatology.

[57]  P. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[58]  M. Raebel,et al.  Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[59]  S. Mauss,et al.  Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. , 2008, Current drug abuse reviews.

[60]  E. Vrettou,et al.  Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. , 2007, Hippokratia.

[61]  Michal Abrahamowicz,et al.  Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. , 2005, American journal of epidemiology.

[62]  E. Duflo,et al.  How Much Should We Trust Differences-in-Differences Estimates? , 2001 .

[63]  J. Mullahy Specification and testing of some modified count data models , 1986 .

[64]  D. Mosley,et al.  Random assignment of proxy event dates to unexposed individuals in observational studies: An automated technique using SAS ® . , 2012 .

[65]  石黒 真木夫,et al.  Akaike information criterion statistics , 1986 .